Press Release

India Urology Drugs Market to Establish Growth with Impressive CAGR until FY2029

Increasing healthcare infrastructure and a supportive regulatory environment are the major drivers for the India Urology Drugs Market.

 

According to TechSci Research report, “India Urology Drugs Market Industry Size, Share, Trends, Competition, Opportunity and Forecast, 2019-2029”, India Urology Drugs Market has valued at USD 1.02 billion in 2023 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 6.90 % through 2029. This can be due to collaborations and partnerships among leading companies with a diverse approach to merge the expertise of individual companies and to strengthen their position in the market. The aging population is a significant driver of the demand for urology drugs. As individuals age, they become more susceptible to a range of urological conditions, including benign prostatic hyperplasia (BPH), urinary incontinence, kidney stones, and erectile dysfunction. The higher incidence of these conditions among the elderly drives the demand for urology drugs, which are often used in the management and treatment of these conditions. Enlargement of the prostate is common in older men, and it can lead to urinary symptoms. Many urology drugs are prescribed to manage the symptoms of BPH, reducing urinary frequency and improving urine flow. Aging is a significant risk factor for urinary incontinence. Urology drugs, including anticholinergic medications, can help manage and control this condition, improving the quality of life for older individuals. Erectile dysfunction becomes more prevalent with age. Medications like phosphodiesterase type 5 (PDE5) inhibitors, including Viagra and Cialis, are commonly prescribed to address this issue, increasing the demand for such drugs among older adults. The risk of developing kidney stones tends to increase with age. Urology drugs may be used to manage the pain and assist in the passage of kidney stones. The aging process can lead to changes in bladder function, including increased urinary frequency and urgency. Urology drugs can help manage these symptoms.

 

Browse over XX market data Figures and spread through XX Pages and an in-depth TOC on " India Urology Drugs Market.”

 

In June 2022, Austrak, an Indian pharmaceutical company headquartered in Hyderabad, Telangana, has recently introduced a new super-specialty division. This division is dedicated to offering approximately 73 high-value products in the fields of nephrology and urology. Austrak, known for its strong presence in ophthalmology over the past 12 years, is a leading healthcare group with a focus on innovation. The company's primary areas of operation encompass pharmaceuticals and surgical products. Austrak's mission is to provide products and services that have a significant positive impact on people's lives by contributing to the prevention, diagnosis, and treatment of diseases. Patent expirations present challenges in the India Urology Drugs Market, as they do in the pharmaceutical industry worldwide. When the patent for a urology drug expires, it opens the door for the entry of generic drug manufacturers into the market. This increased competition can lead to a significant drop in the price of the drug, impacting the revenue of the original drug manufacturer. As generic versions of urology drugs become available, the original brand-name drug may lose a substantial portion of its market share. Patients and healthcare providers may opt for more affordable generic alternatives. With the introduction of generic versions, price erosion can occur, driving down the cost of urology drugs. While this can benefit patients by making medications more affordable, it can be a challenge for brand-name drug manufacturers. The entry of multiple generic manufacturers can lead to a fragmented market with various versions of the same drug, potentially creating confusion among healthcare providers and patients.

India Urology Drugs Market is segmented based on Drug Class, Type, Application, Distribution Channel, and by region.

Based on the Application, India Urology Drugs Market is segmented into Benign Prostatic Hyperplasia (BPH), Prostate Cancer, Urinary Incontinence, Kidney/Bladder Stone, Erectile Dysfunction, Others. Erectile dysfunction (ED), commonly known as impotence, is a medical condition characterized by the consistent or recurrent inability to achieve or maintain an erection sufficient for sexual intercourse. It is a common sexual health issue that can affect men of all ages but is more prevalent as men get older. ED can be caused by a wide range of physical, psychological, or lifestyle factors, and it can have a significant impact on a man's overall well-being and self-esteem. The primary symptom of ED is the inability to achieve or sustain an erection firm enough for sexual intercourse. It's important to note that occasional difficulties with achieving or maintaining an erection are normal and not necessarily indicative of ED. ED is typically diagnosed when the issue is persistent. A healthcare provider may diagnose ED through a physical examination, medical history assessment, and a discussion of symptoms. Blood tests may be performed to check for underlying medical conditions, and sometimes imaging studies or special tests to assess blood flow may be recommended. Based on Region, North India held the largest share in the India Urology Drugs Market. North India includes economically prosperous regions, which can lead to higher healthcare spending and a greater ability to afford urology drugs. North India is home to several major pharmaceutical companies and manufacturing hubs, making it a convenient location for the production and distribution of urology drugs. The presence of renowned healthcare institutions and research centers in North India fosters research, development, and adoption of advanced urology treatments and drugs. Government initiatives and healthcare policies in the region can influence the healthcare landscape and the urology drugs market.

 

Some of the major companies operating in the India Urology Drugs Market include:

  • Astellas Pharma India Pvt Ltd
  • Endo Pharmaceuticals
  • Sanofi India
  • Pfizer Ltd.
  • Innovexia Lifesciences
  • Salvus Pharma
  • Silhos Pharma Ltd.

 

Download Free Sample Report

Customers can also request for 10% free customization on this report.


“Certain areas, particularly in North America, are projected to exert significant demand for Urology Drugs. The growth in the competitive landscape and the presence of well-established companies in the market, committed to enhance the overall wellbeing of people each year, are expected to contribute to a remarkable growth of the India Urology Drugs Market in the forecast period," said Mr. Karan Chechi, Research Director with TechSci Research, a research-based Global management consulting firm.

India Urology Drugs Market by Drug Class (Anticholinergic/ Antispasmodic Agents, Skeletal Muscle Relaxants, Alpha Blockers, Others), By Type (Original Drugs v/s Generic Drugs), By Application (Benign Prostatic Hyperplasia (BPH), Prostate Cancer, Urinary Incontinence, Kidney/Bladder Stone, Erectile Dysfunction, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online), By Region, By Competition Forecast & Opportunities, 2019-2029F has evaluated the future growth potential of India Urology Drugs Market and provides statistics & information on market size, structure, and future market growth. The report intends to provide innovative market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in India Urology Drugs Market.


Contact

Mr. Ken Mathews

Techsci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

Tel: +13322586602

Email: [email protected]               

Website: www.techsciresearch.com               

Relevant News